CTKB Q2 2023 Earnings — Cytek Biosciences, Inc. Revenue & Financial Results | Market Cap Arena

CTKBCytek Biosciences, Inc.

$553M

Q2 2023 Earnings

Healthcare Medical - Devices

Income Statement

Revenue

$50M+23.7% YoY

Gross Profit

$28M56.7% margin

Operating Income

-$9M-18.4% margin

Net Income

-$4M-8.8% margin

EPS (Diluted)

$-0.03

QoQ Revenue Growth

+34.0%

Cash Flow

Operating Cash Flow

-$3M

Free Cash Flow

-$4M

Stock-Based Comp.

$6M

Balance Sheet

Total Assets

$525M

Total Liabilities

$101M

Stockholders' Equity

$424M

Cash & Equivalents

$132M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$50M	$40M	+23.7%
Gross Profit	$28M	$25M	+14.7%
Operating Income	-$9M	-$891,000	-924.4%
Net Income	-$4M	-$598,000	-633.8%

Revenue Segments

Product

$40M81%

Service

$9M19%

Geographic Segments

UNITED STATES

$31M63%

EMEA

$9M18%

Asia Pacific

$7M14%

Other

$2M4%